The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®. The new vaccine is indicated for active immunization to prevent COVID-19 caused ...

Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

HHS Secretary Robert F. Kennedy Jr. says Moderna (MRNA) has agreed to do another clinical trial to back its newly approved ...

The price volatility for the three companies may continue in Monday’s stock markets. On May 31, Moderna (MRNA) won the U.S.

The private equity firm will take a minority stake in Felix Pharma to back its growth in the expanding generics segment for ...

Moderna Inc. has agreed to do a placebo-controlled trial of its new COVID vaccine that was recently approved by U.S.

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.